Ipca Laboratories News, Corporate filings and Earnings/Conference Calls

Name: Latest research reports of Ipca Laboratories Ltd. authored by Motilal Oswal and published by - Trendlyne research reports.
Item: Ipca Laboratories Ltd.
Rating: 5
Author: Motilal Oswal

Keep track of all breaking news and updates on Ipca Laboratories from all sources in a single place.

Ipca Laboratories Ltd.

02 Apr 2026

1456.00

-2.17%

Company Update

Ipca Laboratories Ltd - 524494 - Announcement under Regulation 30 (LODR)-Newspaper Publication

BSE India

Newspaper Notice issued by the Company regarding transfer of physical shares.

pdf

Ipca Laboratories Ltd.

17 Mar 2026

1456.00

-2.17%

Ipca Labs rallies 4%, stock hits 52-week high; analysts see more upside

Business Standard

Ipca Labs hit a 52-week high of 1,624 on the BSE in Tuesday's intra-day trade amid heavy volumes and was seen inching towards its record high of 1,757.55 touched on January 3, 2025.

Ipca Laboratories Ltd. is trading above its 200 day SMA of 1419.5

Ipca Laboratories Ltd.

17 Mar 2026

1456.00

-2.17%

Growth visibility improving in DF and exports

Buy: Ipca Laboratories Ltd.

Target

Motilal Oswal

IPCA is taking multiple initiatives for its domestic formulation (DF) segment, such as cardiology portfolio restructuring, Zerodol franchise strengthening, RA focus within pain management, and entry into high-end cosmo-dermatology, to boost its growth prospects.

Ipca Laboratories Ltd. is trading below its 30 day SMA of 1521.0

Ipca Laboratories Ltd.

16 Mar 2026

1456.00

-2.17%

SAST

Ipca Laboratories Ltd - 524494 - Closure of Trading Window

BSE India

Closure of Trading Window

pdf

Ipca Laboratories Ltd.

06 Mar 2026, 12:00AM

1456.00

-2.17%

Ipca Laboratories (IPCA IN) Management Meet Update Steady growth visibility BUY

Buy: Ipca Laboratories Ltd.

Target

Prabhudas Lilladhar

We interacted with the management of IPCA Laboratories (IPCA) to assess its medium-term growth trajectory. The company is prioritizing disciplined execution over aggressive diversification, with a clear focus on strengthening its core businesses while building growth levers. Domestic formulations and branded generics which now contribute 45% of revenues and ~70% of EBITDA, continued to outperform market and grow at healthy levels. We expect IPCA to deliver revenue growth ex Unichem at +11% over FY26-28E with normalization in export generic and API business. This will aid operating...

Ipca Laboratories Ltd. has an average target of 1806.67 from 3 brokers.

Ipca Laboratories Ltd.

18 Feb 2026

1456.00

-2.17%

Broker's Call: Ipca Laboratories (Buy)

Business Line

PL Capital

Ipca Laboratories Ltd.'s price crossed below 100Day SMA today

Ipca Laboratories Ltd.

17 Feb 2026

1456.00

-2.17%

Ipca Laboratories (IPCA IN) Q3FY26 Result Update Margin surprise BUY

Buy: Ipca Laboratories Ltd.

Recommendation Target

Prabhudas Lilladhar

Ipca reported strong EBITDA of Rs5.3bn (up 19% YoY) which was 10% above our estimates. Company has witnessed 400bps GMs expansion ex Unichme for 9MFY26 which should sustain given product mix and softer raw material prices. Export API business witnessed recovery in 9MFY26 with 26% YoY growth. Domestic formulation business, which now contributes 40% of revenues and ~55% of EBITDA, continued to outperform and grow at healthy levels. We believe 1) recovery in API segment 2) higher margins ex Unichem 3) steady...

Number of FII/FPI investors decreased from 254 to 248 in Dec 2025 qtr

Ipca Laboratories Ltd.

17 Feb 2026

1456.00

-2.17%

Ipca Laboratories

Buy: Ipca Laboratories Ltd.

Target

ICICI Direct

Revenue break-up Q3FY26 Formulations: 64% (domestic: 41%, export: 22% - export generic: 11%, export institutional: 2%, export branded: 9%), APIs: 13% (export API: 10%, domestic API: 3%), subsidiaries: 23%...